Testing and Targeting KRAS-Mutant NSCLC

 

P

Assessment of Co-Occurring Genomic Alterations in NSCLC

By Paul Hofman 3 Videos
103 views
November 10, 2022
This video was recorded prior to the FDA granting approval to Adagrasib (Krazati) on December ...
read more ↘
0 Comments
Login to view comments. Click here to Login
Testing and Targeting KRAS-Mutant NSCLC
06:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "3-Year Results of the IFCT-1701 DICIPLE P…

Feat. A. Toffart
33:14
Benjamin Herzberg

Direct KRAS Inhibition in NSCLC: Past, Present, and Future

09:17
Shirish Gadgeel

The Data on Novel KRAS G12C Inhibitors: Focus on Adagrasib

21:21
Johns Hopkins

KRASG12C Mutation in NSCLC: Current Data and Future Directions

Feat. S. Rosner
14:37
OncoAlert

mNSCLC: Targeted Therapies Update

Feat. S. Popat
10:29
NYU Langone

FDA Approval of Adagrasib in KRAS G12Cm NSCLC

Feat. J. Sabari
08:22
ESMO 2022 Conference Coverage

ESMO 2022 on the Additional Practice-Informing Adverse Event Pattern…

Feat. J. Zhang
24:33
Paul Hofman

Assessment of Co-Occurring Genomic Alterations in NSCLC

35:51
Yale Cancer Center

Advancements in NSCLC: Multidisciplinary Case Panel Discussion

Feat. S. Benaderet, M. Cohenuram, S. Goldberg, V. Mase Jr, D. Rudolph
20:37
Jia Luo

Taking on Goliath: Targeting KRAS in NSCLC

18:14
Janakiraman Subramanian

Understanding KRAS G12C Positive Lung Cancer

29:00
GRACE

Therapeutic Options in Driver-Mutation Positive mNSCLC Refractory to…

Feat. A. Desai